Perjeta Archives -

Perjeta

Roche’s Herceptin/Perjeta combo product nears EU approval

Phil Taylor CHMP, herceptin, Perjeta, Phesgo, Roche, Xofluza 0 Comment

The EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin

Roche’s Herceptin/Perjeta combo product nears EU approval

https://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/

Keeping up the PACE at the Scottish Medicines Consortium

Market Access/ News/ News

After a nay from NICE, Scotland says aye to J&J’s Spravato

Phil Taylor Cablivi, Janssen, NICE, Perjeta, Polivy, Roche, Sanofi, Scottish Medicines Consortium, Spravato 0 Comment

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

News/ News/ Patients

Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer

Phil Taylor NICE, Perjeta, Roche 0 Comment

Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer

Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer

https://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/

Market Access/ News/ News/ News/ Oncology

Roche’s Perjeta combo approved in Europe for early breast cancer

Linda Banks breast cancer, cancer, cancer drug, HER2-positive breast cancer, Oncology, Perjeta 0 Comment

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

Roche’s Perjeta combo approved in Europe for early breast cancer

https://pharmaphorum.com/news/roches-perjeta-approved-early-breast-cancer/

Trending

Perjeta

Login